中国P站

Cancer immunotherapy; Immune checkpoints; CTLA- 4; PD-1/PD-L1; Combination therapy; Biomarkers; Personalized medicine

Introduction

Immune checkpoints are crucial regulators of the immune system, maintaining self-tolerance and preventing autoimmunity. However, cancer cells exploit these checkpoints to evade immune surveillance, leading to tumor progression and immune evasion [1,2]. Inhibiting immune checkpoints, such as cytotoxic T-lymphocyte antigen 4 (CTLA- 4) and programmed cell death protein 1 (PD-1), has revolutionized cancer treatment by restoring anti-tumor immunity. Here, we discuss the latest developments in targeting immune checkpoints for cancer immunotherapy [3].

Immune checkpoint inhibitors

Monoclonal antibodies targeting CTLA-4, such as ipilimumab, have demonstrated remarkable efficacy in treating melanoma and other malignancies [4]. Similarly, antibodies against PD-1 (e.g., pembrolizumab, nivolumab) and its ligand PD-L1 have shown significant clinical benefits across various cancer types, including lung cancer, renal cell carcinoma, and Hodgkin lymphoma. The approval of these immune checkpoint inhibitors has transformed the treatment landscape, offering durable responses and improved survival outcomes in patients with advanced cancer.

Combination therapies

While immune checkpoint inhibitors have shown impressive results, not all patients respond to monotherapy, necessitating the exploration of combination strategies [5]. Combinations of immune checkpoint inhibitors with other immunotherapeutic agents, chemotherapy, targeted therapy, or radiotherapy have been investigated to enhance antitumor immunity and overcome resistance mechanisms. For example, the combination of ipilimumab and nivolumab has demonstrated superior efficacy compared to monotherapy in melanoma and other tumor types.

Biomarkers and personalized medicine

Identifying predictive biomarkers is crucial for patient selection and treatment optimization in cancer immunotherapy. PD-L1 expression on tumor cells or immune cells has been widely used as a biomarker to predict response to PD-1/PD-L1 inhibitors [6]. However, the predictive value of PD-L1 expression varies across different cancer types and treatment regimens. Other potential biomarkers, such as tumor mutational burden (TMB) and immune gene signatures are being explored to improve patient stratification and personalize treatment strategies.

Novel immune checkpoints and targets

In addition to CTLA-4 and PD-1/PD-L1, emerging immune checkpoints and targets are being investigated to expand the repertoire of immunotherapy options [7,8]. Examples include lymphocyte activation gene 3 (LAG-3), T-cell immunoglobulin and mucindomain containing-3 (TIM-3), and indoleamine 2,3-dioxygenase 1 (IDO1). Preclinical and clinical studies evaluating inhibitors of these novel checkpoints alone or in combination with existing therapies are ongoing, with the aim of enhancing anti-tumor immune responses and overcoming resistance mechanisms.

Conclusion

Targeting immune checkpoints has revolutionized cancer immunotherapy, offering new hope for patients with advanced malignancies. Immune checkpoint inhibitors have demonstrated remarkable clinical benefits across a wide range of cancer types, leading to their widespread adoption in clinical practice. However, challenges such as resistance mechanisms and biomarker identification remain, highlighting the need for continued research and innovation in this field. Novel strategies targeting emerging immune checkpoints and personalized medicine approaches hold promise for further improving outcomes and advancing the era of precision cancer immunotherapy.

References

1. Fine PE (1995). Lancet 346: 1339-1345.

, , Crossref

2. Fallahi-Sichani M, Flynn JL, Linderman JJ, Kirschner DE (2012). J Immun J 188: 3169-3178.

, , Crossref

3. Marino S, El-Kebir M, Kirschner DE (2011)J Theor Biol 280: 50-62.

, , Crossref

4. Fallahi-Sichani M, El-Kebir M, Marino S, Kirschner DEK, Linderman J (2011). J Immun J 186: 3472-3483.

, , Crossref

5. Choi SH (2019). Biochim Biophys Acta Gene Regul Mech 1862: 771-785.

, , Crossref

6. Yang Y (2020). Cell Death Dis 11: 477.

, , Crossref

7. Liu Y (2018)33: 721-735.

, , Crossref

8. Berger AC (2018)33: 690-705.

, , Crossref